Welcome to our dedicated page for Nkarta news (Ticker: NKTX), a resource for investors and traders seeking the latest updates and insights on Nkarta stock.
Nkarta, Inc. reports developments as a clinical-stage biotechnology company developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for autoimmune diseases. Company updates center on NKX019, an investigational CAR-NK cell therapy for B cell-mediated autoimmune diseases, and on the Ntrust-1 and Ntrust-2 clinical studies.
Recurring news themes include FDA protocol discussions, outpatient dosing plans, dose-escalation updates, B-cell depletion data, preclinical and clinical presentations, quarterly financial results, cash runway commentary, workforce and operating updates, and participation in healthcare and investor conferences.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nkarta, Inc. (Nasdaq: NKTX) reported its Q1 2023 financial results and corporate highlights. The company, focused on developing engineered natural killer (NK) cell therapies, announced:
1. Clinical updates for NKX101 expected in Q2 2023 and NKX019 in H2 2023.
2. Cash and cash equivalents of $332.1 million as of March 31, 2023.
3. Cash runway anticipated to fund operations into 2025.
4. Net loss of $30.8 million, or $0.63 per share, for Q1 2023.
5. R&D expenses of $26.1 million and G&A expenses of $8.2 million for Q1 2023.
The company plans to present additional clinical data for both NKX101 and NKX019 in their respective ongoing Phase 1 trials. Nkarta also announced the resignation of its CFO and business officer, Nadir Mahmood, PhD, effective June 30, 2023.